Massachusetts defeat looks set to water down US Pres Obama's health reform plans

21 January 2010

The defeat for the Democrats in the special Senate election in the US state of Massachusetts ' which elected little-known Republican Scott Brown to the seat previously held by Senator Ted Kennedy who died last year - has thrown President Barack Obama's controversial $849 billion Health Care Reform Bill into doubt, as the loss of the filibuster-proof Senate majority might force him into some sort of a compromise (The Pharma Letter January 21).

Although there has been little in the way of a formal statement from the White House, President Obama yesterday - in an interview with ABC News - urged lawmakers to "coalesce" around the parts of proposed health reform on which they agreed, signaling he might support a scaled-back overhaul of legislation that had been his number one domestic policy priority. The President has, however, stated: 'The same thing that swept Scott Brown into office swept me into office. People are angry, and they're frustrated. Not just because of what's happened in the last year or two years, but what's happened over the last eight years.'

He also warned Democrats in Congress not to "jam" a health care reform bill through now that they have lost their commanding majority in the Senate, and said they must wait for newly- elected Mr Brown to be sworn into office, telling ABC he rejected a 'dirty quick-fix' on health care. He said: "The people of Massachusetts spoke; he [Scott Brown] has got to be part of that process." However, the president said it was important for Americans to understand that core elements of the bill such as cost containment and insurance reform were vital.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical